Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sublingual Immunotherapy in Peanut-allergic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Peanut IgE \> 7kU/L (\> 2kU/L for children aged 2 years and under) AND~* History of significant clinical symptoms within 60 minutes after the ingestion of peanuts.~Exclusion Criteria:~* History of severe life-threatening anaphylaxis to peanut, OR~* Medical history that would prevent a DBPCFC to peanut, OR~* Subjects with wheat or oat allergy (which are used in the placebo), OR~* Unable to cooperate with challenge procedures, OR~* Unable to be reached by telephone for follow-up

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Blinded Peanut SLIT (Type: ACTIVE_COMPARATOR): Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
- Blinded Placebo SLIT (Type: PLACEBO_COMPARATOR): Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
- Ext. maint. open label peanut SLIT (Type: OTHER): After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
- Early unblinded peanut SLIT (Type: OTHER): Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
- Pilot peanut SLIT rollover cohort (Type: OTHER): Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).